Vimarsana
Biggest News Aggregation in the World

Page 2 - Abilify Maintena News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Abilify Maintena. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Abilify Maintena Today - Breaking & Trending Today

Against Her Will - Vimarsana News

Against Her Will

Under Canada's Mental Health Act, doctors don’t have to get a patient’s consent for treatment — or the consent of a substitute decision maker. They have what’s known as the patient’s “deemed consent” to administer any treatment that’s been approved by the director of the mental health facility.

Abilify Maintena® 960 mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of - Vimarsana News

Abilify Maintena® 960 mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of

Aripiprazole’s new long-acting injectable (LAI) formulation enables continuous exposure to medication for two months1.Windsor, United Kingdom/Valby, Denmark, 27 March, 2024 – Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has ap...

The Role of the Pharmacist in Long-Acting Injectable Therapies for Schizophrenia and Bipolar Disorder - Vimarsana News

The Role of the Pharmacist in Long-Acting Injectable Therapies for Schizophrenia and Bipolar Disorder

These therapies can improve treatment adherence for patients, especially for those with a history of poor or uncertain adherence.

Otsuka's new formulations to offset Abilify Maintena dual patent expiry impact, says GlobalData - Vimarsana News

Otsuka's new formulations to offset Abilify Maintena dual patent expiry impact, says GlobalData

Otsuka Pharmaceutical is poised for a strategic transition as it approaches the loss of market exclusivity of Abilify Maintena (Aripiprazole) in Europe and the US in October 2024. This significant development signals a forthcoming shift in the drug’s sales trajectory, highlighting Otsuka’s readiness to embrace ...

H. Lundbeck A/S (OTCMKTS:HLUYY) Trading Down 0% - Vimarsana News

H. Lundbeck A/S (OTCMKTS:HLUYY) Trading Down 0%

H. Lundbeck A/S (OTCMKTS:HLUYY – Get Free Report) fell 0% on Monday . The stock traded as low as $22.00 and last traded at $22.00. 7,500 shares traded hands during trading, an increase of 327% from the average session volume of 1,758 shares. The stock had previously closed at $22.01. Analyst Ratings Changes A number […]